To the Editor: Microcystic adnexal carcinoma (MAC) is an uncommon eccrine adnexal tumor. [1] [2] [3] Mohs micrographic surgery (MMS) is reported in the literature to be among the most effective surgical options. 2 We aimed to describe the demographics of a large series of patients with MAC, with long-term follow-up outcome data.
This retrospective chart review of biopsy-proven MAC was performed with institutional review board approval. Statistical analysis was performed with SAS version 9.3 (SAS Institute Inc, Cary, NC). Follow-up was reviewed until date of death or last documented patient contact. The Kaplan-Meier method and Cox proportional hazards regression models were used.
We identified 67 patients with MAC during 1986-2016. Demographics and tumor characteristics (Table I ) and sites of involvement for each tumor (Fig 1) Fifty-one patients with MAC diagnosed before 2011 were treated with MMS at our institution. Of these, 47 patients had $5 years of follow-up after MMS (mean 12.6 years), and 2 of 47 patients (4.3%) had recurrences. Overall mortality rate at 5 years was 8.0% (95% CI 0%-15.5%). Four additional patients were treated with MMS at an outside institution; 1 died of MAC. Among all 55 patients treated with MMS, the disease-specific mortality rate at 5 years was 2% (95% CI 0%-5.8%). In addition, larger tumor size most likely increased the risk for occult tumor spread, which explains the significantly increased rates of recurrence. MAC is known to be poorly responsive to radiotherapy, although this option may be considered as an alternative to surgery for more aggressive and extensive tumors. 4 Three of our patients underwent adjuvant radiotherapy for recurrent MAC, and 2 had progressive disease. One patient underwent MMS and adjuvant radiotherapy for recurrent MAC, with subsequent fatal metastasis to skin, lymph nodes, and lung. We also found no association between prior radiotherapy and recurrence of MAC. In addition, no primary MAC was found within a prior radiation field.
The limitations of this study include the retrospective design and the tertiary nature of our practice. In this large, single-institution series of patients with MAC, we found a high long-term cure rate for MAC when MMS is used and an increased hazard of recurrence with large tumor size. To the Editor: Evidence concerning the treatment of moderate-to-severe psoriasis with interleukin (IL) 17A antibody after rebound or relapse due to the discontinuation of an antieIL-17 receptor antibody is limited.
We conducted a monocentric retrospective study on adult patients treated with secukinumab during June 2016-June 2017 after a relapse of moderate-to-severe plaque psoriasis (defined as a psoriasis area and severity index [PASI] of $12) or a severe form of psoriasis (pustular or eythrodermic) after brodalumab discontinuation. Brodalumab was administered during the extension phase of Amgen's protocols. The abrupt brodalumab discontinuation was due to the interruption of the drug development program in June 2015. The primary efficacy outcome was the PASI. Secondary efficacy outcomes included body surface area and the American College of Rheumatology response criteria to assess functional disability in patients with psoriasis arthritis (PSA). 1 Rebound was defined as a PASI of $125% from baseline or new generalized pustular, erythrodermic, or more inflammatory psoriasis occurring within 3 months of therapy discontinuation. A relapse was defined as a 50% loss of the maximum PASI improvement from baseline. 2, 3 In total, 139 patients in our department received brodalumab. All patients relapsed after a variable period of treatment discontinuation. Thirty patients received secukinumab after discontinuation of brodalumab and were included in the analysis. The remaining patients were successfully treated with methotrexate, antietumor necrosis factor antibodies, or ustekinumab. The mean treatment duration with brodalumab was 160 (range 24-240) weeks. PASI 90 (ie, a 90% improvement from baseline PASI) was obtained in all these patients before drug discontinuation. The mean duration between brodalumab discontinuation and psoriasis relapse was 9 (range 2-24) weeks. The characteristics of the population are summarized in Table I . Of note, the severity of psoriasis after discontinuation of brodalumab was higher than the severity at baseline ( Table I ). The mean time lapse between brodalumab
